Blood Purification Medical Devices Revolutionizing the Future of Health from Cancer to COVID
- Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 3, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at medical device advancements for blood purification, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. Read the full article on Investorideas.com https://www.investorideas.com/News/2024/biotech/06030Blood-Purification-Medical-Devices.asp According to Straits Research, "The global blood purification equipment market size was valued at USD 17,755.6 million in 2021.
- 06/03/2024
|
Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies
- Phase 1 Clinical Trials of the Hemopurifier® Designed to Include Patients With Solid Tumors Who Have Stable or Progressive Disease During Anti-PD-1 Monotherapy Treatment, Such as Keytruda® of Opdivo® Interested Clinical Sites Have Initiated Submissions For Ethics Committee Review SAN DIEGO , June 3, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided the following update on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®. "We continue to make progress preparing for our planned, safety, feasibility and "dose finding" oncology trials in Australia and India, and want to provide our shareholders and other constituents with an update, stated Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical.
- 06/03/2024
|
Aethlon Medical Announces Pricing of $4.7 Million Public Offering
- SAN DIEGO , May 15, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of a public offering of an aggregate of 8,100,000 shares of its common stock (or pre-funded warrants in lieu thereof), Class A warrants to purchase up to 8,100,000 shares of common stock, and Class B warrants to purchase up to 8,100,000 shares of common stock, at a combined public offering price of $0.58 per share (or pre-funded warrant) and accompanying warrants. The warrants will have an exercise price of $0.58 per share, subject to an adjustment, will be exercisable immediately upon issuance and, in the case of Class A warrants, will expire on the fifth anniversary of the original issuance date, and in the case of Class B warrants, will expire on the one year anniversary of the original issuance date.
- 05/15/2024
|
Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma
- Translational Study Provides Pre-Clinical Evidence to Support The Design of a Phase 1 Study of the Hemopurifier In Cancer Patients With Solid Tumors Treated With Anti-PD-1 Antibodies SAN DIEGO , May 10, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced positive results from an in vitro binding study of its Hemopurifier® in removing extracellular vesicles (EVs) from plasma. The translational study provides pre-clinical evidence to support Aethlon's planned phase 1 safety, feasibility and dose-finding clinical trials of the Hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.
- 05/10/2024
|
Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices
- Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential Synergies With its First-in-Class Hemopurifier® Blood Filtration System SAN DIEGO , Feb. 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it entered into a Materials Transfer Agreement (MTA) with Santersus AG, a Zurich-London based, privately held therapeutic medical device company, for Santersus' NucleoCapture and HemoNucleoCapture devices. Under the terms of the MTA, Santersus will supply Aethlon with NucleoCapture and HemoNucleoCapture devices, designed to remove Neutrophil Extracellular Traps (NETs), which are toxic to tissues and organs and are implicated in the pathophysiology of cancer, sepsis, autoimmune diseases, such as lupus, and ischemia reperfusion injury in organ transplantation.
- 02/21/2024
|
Aethlon Medical, Inc. (AEMD) Q3 2024 Earnings Call Transcript
- Aethlon Medical, Inc. (AEMD) Q3 2024 Earnings Call Transcript
- 02/14/2024
|
Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update
- Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , Feb. 14, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2023 and provided an update on recent developments.
- 02/14/2024
|
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024
- SAN DIEGO , Feb. 7, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2023, at 4:15 p.m. ET on Wednesday, February 14, 2024.
- 02/07/2024
|
Aethlon Medical, Inc. (AEMD) Q2 2024 Earnings Call Transcript
- Aethlon Medical, Inc. (NASDAQ:AEMD ) Q2 2024 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Michael Miller - Rx Communications, IR Jim Frakes - Interim CEO and CFO Steven LaRosa - CMO Guy Cipriani - COO Conference Call Participants Marla Marin - Zacks Thomas McGovern - Maxim Group Vernon Bernardino - H.C. Wainwright Operator Good day, and welcome to the Aethlon Medical Second Quarter Fiscal 2024 Earnings and Corporate Update Call.
- 11/14/2023
|
Aethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate Update
- Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , Nov. 14, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2023 and provided an update on recent developments.
- 11/14/2023
|
Aethlon Medical Announces Appointment of James B. Frakes, M.B.A.
- SAN DIEGO , Nov. 13, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that James B. Frakes, M.B.A.
- 11/13/2023
|
Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2023
- SAN DIEGO , Nov. 6, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening viral infections and for use in organ transplantation, today announced that it will issue financial results for its second quarter ended September 30, 2023, at 4:15 p.m. ET on Tuesday, November 14, 2023.
- 11/06/2023
|
Aethlon Receives Clearance From Drug Controller General of India For Potential Phase 1 Trial of its Hemopurifier® in Oncology
- SAN DIEGO , Oct. 10, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening viral infections and for use in organ transplantation, today announced that it has received clearance from the Drug Controller General of India (DCGI), the central drug authority in India, to conduct a phase 1 safety, feasibility and dose-finding trial of the company's Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®. The trial is expected to begin following completion of an internal in vitro binding study of relevant targets, and subsequent approval by the respective Ethics Boards of interested sites in India.
- 10/10/2023
|
Aethlon Announces Reverse Stock Split
- SAN DIEGO , Oct. 4, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's common stock, effective at 5:00 p.m. ET on October 4, 2023.
- 10/04/2023
|
Aethlon Medical to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- SAN DIEGO , Aug. 30, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that Steven LaRosa, M.D., Chief Medical Officer, and James Frakes, Chief Financial Officer, will present a company overview on Tuesday, September 12 at 4:30 PM EST, during the H.C.
- 08/30/2023
|
Aethlon Medical, Inc. (AEMD) Q1 2024 Earnings Call Transcript
- Aethlon Medical, Inc. (NASDAQ:AEMD ) Q1 2024 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Jim Frakes – Chief Financial Officer Charles J. Fisher, Jr. – Chief Executive Officer Steven LaRosa – Chief Medical Officer Conference Call Participants Marla Marin – Zacks Vernon Bernardino – H.C.
- 08/10/2023
|
Aethlon Medical Announces Fiscal First Quarter Financial Results and Provides Corporate Update
- Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , Aug. 10, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today reported financial results for its fiscal first quarter ended June 30, 2023 and provided an update on recent developments.
- 08/10/2023
|
Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 10, 2023
- SAN DIEGO , Aug. 3, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it will issue financial results for its first quarter ended June 30, 2023, at 4:15 p.m. EST on Thursday, August 10, 2023.
- 08/03/2023
|
Aethlon Medical Signs Collaboration Agreement with 34 Lives to Evaluate the Ability of the Hemopurifier® to Expand the Utility of Unused, Donated Kidneys for Transplant
- Proof-of-Concept Studies to Support the Use of the Hemopurifier in the Ex Vivo Organ Perfusion Circuit SAN DIEGO, July 24, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it has signed a Collaboration Agreement with 34 Lives, PBC, to investigate the use of Aethlon's proprietary Hemopurifier® technology and 34 Lives' organ evaluation and preservation system, with the goal of increasing the supply of useable donated kidneys for human transplant. Financial terms of the agreement were not disclosed.
- 07/24/2023
|
Aethlon Medical to Release Fourth Quarter and Year End Financial Results and Host Conference Call on June 28, 2023
- SAN DIEGO , June 22, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it will issue financial results for its fourth quarter ended March 31, 2023, at 4:15 p.m. EST on Wednesday, June 28, 2023.
- 06/22/2023
|
Aethlon Medical to Participate in the Healthcare Virtual Conference Presented by Maxim Group and Hosted by M-Vest
- SAN DIEGO , June 14, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious diseases, today announced that Charles J. Fisher, Jr. M.D.
- 06/14/2023
|
Aethlon Medical to Present at the 13th Annual LD Micro Invitational
- SAN DIEGO , June 1, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious diseases, today announced that Guy Cipriani, Senior Vice President and Chief Business Officer, and James Frakes, Chief Financial Officer, will present a company overview at the 13th Annual LD Micro Invitational on Wednesday, June 7, 2023, at 1:30 PM PT. Management will also be participating in one-on-one meetings with investors at this conference being held June 6-8, 2023, in Los Angeles, California.
- 06/01/2023
|
5 Hot Penny Stocks To Watch With The Stock Market Down This Week
- Hot penny stocks to watch this week. This is a significant week for earnings, and mega-cap tech names will headline what's sure to be a volatile week. Next week, the action continues with the upcoming Fed meeting and another rate hike decision.
- 04/24/2023
|
Essential Penny Stock Trading Tools: Maximizing Efficiency
- Use these tips for trading penny stocks efficiently The post Essential Penny Stock Trading Tools: Maximizing Efficiency appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/21/2023
|
Aethlon Medical, Inc. (AEMD) Q3 2023 Earnings Call Transcript
- Aethlon Medical, Inc. (NASDAQ:AEMD ) Q3 2023 Earnings Conference Call February 13, 2023 4:30 PM ET Company Participants Jim Frakes - Chief Financial Officer Steven LaRosa - Chief Medical Officer Guy Cipriani - Chief Business Officer Conference Call Participants Marla Marin - Zacks Anthony Vendetti - Maxim Group Operator Good day, and welcome to the Aethlon Medical Third Quarter Fiscal 2023 Earnings and Corporate Update Call. All participants will be in listen-only mode.
- 02/13/2023
|
Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 13, 2023
- SAN DIEGO , Feb. 6, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its third quarter ended December 31, 2022, at 4:15 p.m. EST on Monday, February 6, 2023.
- 02/06/2023
|
Aethlon Medical to Present at Sequire Biotechnology Conference on February 2nd, 2023
- Presentation on Thursday, February 2nd, 2023 at 10:00 AM ET SAN DIEGO , Jan. 31, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, announced today that it will be presenting virtually at the upcoming Sequire Biotechnology Conference on Thursday, February 2nd, at 10:00 AM ET. Steven LaRosa, M.D.
- 01/31/2023
|
3 Tips for Using Technical Indicators to Find Penny Stocks to Buy
- Can these technical indicators help you make money with penny stocks? The post 3 Tips for Using Technical Indicators to Find Penny Stocks to Buy appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/31/2023
|
Why Is Aethlon Medical (AEMD) Stock Up 50% Today?
- It's not every day that Aethlon Medical (NASDAQ: AEMD ) gets this much attention. AEMD stock is soaring today on unusually high volume.
- 01/30/2023
|
5 Hot Penny Stocks To Watch With Big News This Week
- Penny stocks fueled by news catalysts this week. The post 5 Hot Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/30/2023
|
Aethlon Medical, Inc. (AEMD) Q2 2022 Earnings Call Transcript
- Aethlon Medical, Inc. (NASDAQ:AEMD ) Q2 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Charles Fisher - Chief Executive Officer James Frakes - Senior Vice President and Chief Financial Officer Steven LaRosa - Chief Medical Officer Guy Cipriani - Senior Vice President and Chief Business Officer Conference Call Participants Marla Marin - Zacks Investment Research Thomas McGovern - Maxim Group Operator Good afternoon and welcome to the Aethlon Medical's Second Quarter Fiscal 2022 Earnings and Corporate Update Conference Call. Participants will be in listen-only mode.
- 11/14/2022
|
Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2022
- SAN DIEGO , Nov. 2, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its second quarter ended September 30, 2022, at 4:15 p.m. EST on Monday, November 14, 2022.
- 11/02/2022
|
Aethlon Medical to Present at Two Investor Conferences in September
- SAN DIEGO , Sept. 6, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious diseases, today announced that it will be presenting at two investor conferences in September.
- 09/06/2022
|
Aethlon Medical, Inc.'s (AEMD) CEO Chuck Fisher on Q1 2023 Results - Earnings Call Transcript
- Aethlon Medical, Inc. (NASDAQ:AEMD ) Q1 2023 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Chuck Fisher - CEO Jim Frakes - CFO Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Operator Hello, and welcome to the Aethlon First Quarter Fiscal 2023 Earnings and Corporate Update Conference Call. All participants will be in listen-only mode.
- 08/09/2022
|
10 Top Monkeypox Stocks To Watch Right Now
- 10 monkeypox stocks and monkeypox penny stocks to watch The post 10 Top Monkeypox Stocks To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/04/2022
|
Best Penny Stocks To Buy Premarket on August 3rd? 3 to Watch
- Here's what you need to know about buying penny stocks today The post Best Penny Stocks To Buy Premarket on August 3rd? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/03/2022
|
Best Penny Stocks To Buy Now? 4 Monkeypox Stocks To Watch This Week
- Monkeypox penny stocks to watch this week. The post Best Penny Stocks To Buy Now?
- 08/02/2022
|
Hot Penny Stocks To Buy? 4 Under $3 To Watch This Week
- Are you looking for some hot penny stocks to buy this week?
- 07/25/2022
|
Aethlon Medical, Inc. (AEMD) CEO Dr. Chuck Fisher on Q4 2022 Results - Earnings Call Transcript
- Aethlon Medical, Inc. (NASDAQ:AEMD ) Q4 2022 Results Conference Call June 28, 2022 4:30 PM ET Company Participants Dr. Chuck Fisher - CEO Jim Frakes - CFO Dr. Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Vernon Bernardino - H.C. Wainwright Anthony Vendetti - Maxim Group Operator Good afternoon, and welcome to the Aethlon Medical Fourth Quarter Fiscal 2022 Earnings and Corporate Update Conference Call.
- 06/28/2022
|
Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 28, 2022
- SAN DIEGO , June 21, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its fiscal year ended March 31, 2022, at 4:15 p.m. EST on Tuesday, June 28, 2022.
- 06/21/2022
|
Top Penny Stocks To Watch As Monkeypox Cases Rise
- Monkeypox penny stocks to watch right now The post Top Penny Stocks To Watch As Monkeypox Cases Rise appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/01/2022
|
Check These 3 Penny Stocks Out For Your Watchlist
- Are these penny stocks on your watchlist right now? The post Check These 3 Penny Stocks Out For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/23/2022
|
Penny Stocks To Buy Now? Hot Monkeypox Stocks To Watch Today
- Monkeypox stocks to watch today. The post Penny Stocks To Buy Now?
- 05/20/2022
|
Aethlon Medical to Present at the H.C. Wainwright Global Investment Conference
- SAN DIEGO, May 17, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that it will be presenting at the H.C. Wainwright Global Investment Conference.
- 05/17/2022
|
Aethlon Medical's (AEMD) CEO Chuck Fisher on Q3 2022 Results - Earnings Call Transcript
- Aethlon Medical's (AEMD) CEO Chuck Fisher on Q3 2022 Results - Earnings Call Transcript
- 02/14/2022
|
Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 14, 2022
- SAN DIEGO, Jan. 31, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its third quarter fiscal year 2022, ended December 31, 2021, at 4:15 p.m. EST on Monday, February 14, 2022.
- 01/31/2022
|
Aethlon Medical, Inc. (AEMD) CEO Charles Fisher on Q2 2022 Results - Earnings Call Transcript
- Aethlon Medical, Inc. (AEMD) CEO Charles Fisher on Q2 2022 Results - Earnings Call Transcript
- 11/09/2021
|
Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 9, 2021
- SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its second quarter fiscal year 2022, ended September 30, 2021, at 4:15 p.m. EST on Tuesday, November 9, 2021.
- 11/02/2021
|
Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®
- SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced the publication of a manuscript in the peer-reviewed journal Frontiers in Medicine describing two cases of critically ill COVID-19 patients treated with the Hemopurifier®, Aethlon's therapeutic blood filtration system. The publication, titled "Removal of COVID-19 spike protein, whole virus, exosomes and exosomal microRNAs by the Hemopurifier® lectin-affinity cartridge in critically Ill patients with COVID-19 infection," is available here: https://www.frontiersin.org/articles/10.3389/fmed.2021.744141/full The publication documents two critically ill COVID-19 patients receiving a combined total of nine, six-hour Hemopurifier® treatment sessions.
- 10/12/2021
|
8 Things to Know About Aethlon Medical as Investors Send AEMD Stock Soaring Today
- Aethlon Medical (AEMD) stock is rising higher on Wednesday due to heavy trading despite a lack of news from the company. The post 8 Things to Know About Aethlon Medical as Investors Send AEMD Stock Soaring Today appeared first on InvestorPlace.
- 09/22/2021
|
Aethlon Medical to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
- SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that it will be presenting at the H.C.
- 09/07/2021
|
Aethlon Medical, Inc. (AEMD) CEO Chuck Fisher on Q1 2021 Results - Earnings Call Transcript
- Aethlon Medical, Inc. (AEMD) CEO Chuck Fisher on Q1 2021 Results - Earnings Call Transcript
- 08/09/2021
|
Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update
- SAN DIEGO, Aug. 9, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its first quarter ended June 30, 2021 and provided an update on recent developments. Company Updates Aethlon Medical is continuing the research and clinical development of our Hemopurifier to bind and remove COVID-19 viral particles, including many variant COVID-19 particles of interest and related exosomes.
- 08/09/2021
|
Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 9, 2021
- SAN DIEGO, July 29, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its first quarter fiscal year 2022, ended June 30, 2020, at 4:15 p.m. EST on Monday, August 9, 2021.
- 07/29/2021
|
This Is Why Stocks Are Down Today
- Stocks begin week with the market selling off; why? The post This Is Why Stocks Are Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/19/2021
|
Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update
- SAN DIEGO, June 24, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its fiscal year ended March 31, 2021 and provided an update on recent developments. Company Updates SARS-CoV-2/COVID-19 SARS-COV-2, the causative agent of COVID-19, is a member of the coronavirus family, which includes the original SARS virus, SARS-CoV, and the MERS virus.
- 06/24/2021
|
Aethlon Medical to Release Fourth Quarter Financial Results and Host Conference Call on June 24, 2021
- SAN DIEGO, June 21, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its fourth quarter fiscal year 2021, ended March 31, 2021, at 4:15 p.m. ET on Thursday, June 24, 2021.
- 06/21/2021
|
Aethlon Medical Announces $12.425 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- SAN DIEGO, June 10, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq:AEMD), a medical device technology company focused on unmet needs in global health, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase in a registered direct offering of 1,380,555 shares of its common stock, at a purchase price per share of $9.00, priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about June 14, 2021, subject to the satisfaction of customary closing conditions.
- 06/10/2021
|
AEMD Stock Price: 388.24% Increase Explanation
- The stock price of Aethlon Medical, Inc. (NASDAQ: AEMD) increased 388.24% yesterday. This is why it happened.
- 06/10/2021
|
AEMD, CTEK, AEHL, AMSWA, CKPT, CLNE, SPI, ATOM, PUBM, IMH Stock Prices Gain Intraday
- The stock prices of AEMD, CTEK, AEHL, AMSWA, CKPT, CLNE, SPI, ATOM, PUBM, and IMH have noticeably gained today. The post AEMD, CTEK, AEHL, AMSWA, CKPT, CLNE, SPI, ATOM, PUBM, IMH Stock Prices Gain Intraday appeared first on Pulse 2.0.
- 06/09/2021
|
Aethlon Medical stock explodes 465% on heavy volume as new report about COVID-19 treatment inspires social-media discussion (AEMD)
- Shares of Aethlon Medical exploded as much as 465% to a two-year high on Wednesday despite not releasing any news since last week, when one of its devices showed positive results in two COVID-19 patients. A June 8 report from Zacks Investment Research appeared spark conversation on Reddit, the social-networking platform largely responsible for many of the recent price swings in so-called meme stocks like GameStop and AMC Entertainment.
- 06/09/2021
|
AEMD Stock: The Historic Covid-19 News Sending Aethlon Medical Rocketing 350%+
- Shares of AEMD stock are taking off on Wednesday following the firm's June 3 report of its coronavirus treatment returning promising results. The post AEMD Stock: The Historic Covid-19 News Sending Aethlon Medical Rocketing 350%+ appeared first on InvestorPlace.
- 06/09/2021
|
Aethlon Medical stock more than quadruples on heavy volume
- Shares of Aethlon Medical Inc. skyrocketed more than fourfold on massive volume toward a two-year high in morning trading Wednesday, even though the California-based therapeutic technology company hasn't released any news in nearly a week. On June 3, the company pointed out a "pre-print manuscript" that has not yet completed peer review that was published in "Research Square," highlighting case studies of two critically ill COVID-19 patients who were given access to the company's Hemopurifier through Emergency Use.
- 06/09/2021
|
AEMD Stock Price: Over 290% Increase Pre-Market Explanation
- The stock price of Aethlon Medical, Inc. (NASDAQ: AEMD) increased by over 290% pre-market today. This is why it happened.
- 06/09/2021
|
Why Aethlon Medical Stock Skyrocketing?
- Aethlon Medical Inc (NASDAQ: AEMD) stock surged probably in reaction to Zacks Article 'AEMD: First Ever In Vivo Removal Of COVID Virus From Bloodstream Of An Infected Patient.' The company recently announced the positive results from using its Hemopurifier in treating two critically ill COVID-19 patients, which is available under the FDA emergency use authorization (EUA).
- 06/09/2021
|
Aethlon Medical Publishes Case Studies of Two Critically Ill COVID-19 Patients Treated with the Hemopurifier®
- SAN DIEGO, June 3, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced the publication of a pre-print manuscript highlighting two case studies of critically ill COVID-19 patients treated with the Aethlon Hemopurifier®. Both patients were given access to Hemopurifier® treatment through Emergency Use.
- 06/03/2021
|
Aethlon Medical to Participate in Two Upcoming Healthcare Investor Conferences
- SAN DIEGO, March 1, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that the company will participate in the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021,...
- 03/01/2021
|
Aethlon Medical, Inc. (AEMD) CEO Dr. Chuck Fisher on Q3 2021 Results - Earnings Call Transcript
- Aethlon Medical, Inc. (AEMD) CEO Dr. Chuck Fisher on Q3 2021 Results - Earnings Call Transcript
- 02/10/2021
|
Aethlon Medical Expands Leadership Team with Appointment of Chief Business Officer and Chief Medical Officer
- SAN DIEGO, Jan. 6, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today announced the expansion of its executive team with two key appointments: Guy...
- 01/06/2021
|
Aethlon Medical to Present at the H.C. Wainwright BioConnect 2021 Conference
- SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today announced that the company will participate in the virtual H.C. Wainwright...
- 01/04/2021
|
Aethlon Medical News Alert: Why AEMD Stock Is Rocketing Higher Today
- Aethlon Medical (AEMD) news for Wednesday concerning the progress in an EFS for one of its medical devices has AEMD stock soaring higher. The post Aethlon Medical News Alert: Why AEMD Stock Is Rocketing Higher Today appeared first on InvestorPlace.
- 12/16/2020
|
Aethlon Announces Appointment of Charles J. Fisher, Jr., M.D.
- SAN DIEGO, Nov. 3, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, announced today the appointment of Charles J. Fisher, Jr., M.D., as Chief Executive Officer,...
- 11/03/2020
|
Aethlon Medical, Inc. (AEMD) CEO Tim Rodell on Q2 2021 Results - Earnings Call Transcript
- Aethlon Medical, Inc. (AEMD) CEO Tim Rodell on Q2 2021 Results - Earnings Call Transcript
- 10/29/2020
|
Aethlon Medical (AEMD) Investor Presentation - Slideshow
- The following slide deck was published by Aethlon Medical, Inc. in conjunction with this event..
- 08/16/2020
|
Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update
- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its first quarter ended June 30, 2020 and provided an update on recent developments.
- 08/11/2020
|
We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate
- Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- 08/11/2020
|
We Think Aethlon Medical (NASDAQ:AEMD) Needs To Drive Business Growth Carefully
- Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- 08/11/2020
|
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
- Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
- 08/09/2020
|
Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Update
- Aethlon Medical, Inc. (NASDAQ:AEMD) was the target of a large growth in short interest in June. As of June 30th, there was short interest totalling 283,800 shares, a growth of 17.2% from the June 15th total of 242,200 shares. Based on an average daily volume of 2,350,000 shares, the short-interest ratio is currently 0.1 days. […]
- 07/07/2020
|
Edited Transcript of AEMD earnings conference call or presentation 25-Jun-20 8:30pm GMT
- Q4 2020 Aethlon Medical Inc Earnings Call
- 06/30/2020
|
Aethlon Medical, Inc. 2020 Q4 - Results - Earnings Call Presentation
|
Aethlon Medical, Inc. (AEMD) CEO Timothy Rodell on Q4 2020 Results - Earnings Call Transcript
- Aethlon Medical, Inc. (NASDAQ:AEMD) Q4 2020 Earnings Conference Call June 25, 2020 4:15 P.M. ET Company Participants James Frakes - Chief Financial Officer and
- 06/25/2020
|
Aethlon Medical Announces Fiscal Year Financial Results and Provides Corporate Update
- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its fiscal year ended March 31, 2020 and provided an update on recent developments.
- 06/25/2020
|
Aethlon Medical, Inc. to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / June 25, 2020 / Aethlon Medical, Inc. (NASDAQ:AEMD) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on June 25, 2020 at 4:30 ...
- 06/25/2020
|
Aethlon Medical Presents Hemopurifier® Data at the American Association for Cancer Research 2020 Annual Meeting
- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today released positive ex vivo data demonstrating the ability of a laboratory version of the Company's Hemopurifier® to capture tumor-derived exosomes in several forms of cancer. The data were presented in e-poster format by Dr. Annette Marleau, the Company's Senior Director of Research, at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, on June 22, 2020.
- 06/22/2020
|
The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions
- Biotech stocks rebounded along with the broader market in the week ended June 19. The week was a busy one from the perspective of PDUFA dates, with the FDA issuing approvals...
- 06/21/2020
|
U.S. FDA backs testing of Aethlon device for virus treatment - BNN Bloomberg
- Aethlon reported that U.S. regulators cleared the company to run a feasibility study of its investigational device in as many as 40 patients under intensive care for severe COVID-19.
- 06/18/2020
|
FDA Backs Testing of Device Once Flagged for Covid Speculation
- (Bloomberg) -- As far back as January, stock traders were latching onto Aethlon Medical Inc. and its experimental Hemopurifier device as a potential treatment for the novel coronavirus. After shares quadrupled that month from less than $1 each, market speculation got so heated that the U.S. Securities and Exchange Commission suspended trading in the stock for two weeks.In early March, the company put out a cautious statement, saying it wasn’t sure if the Hemopurifier would help with Covid-19, and even then potentially only in the sickest patients.Flash forward to June 18: Aethlon reported that U.S. regulators cleared the company to run a feasibility study of its investigational device in as many as 40 patients under intensive care for severe Covid-19. Shares climbed as much as 165% to $3.73 a share Thursday to the highest intraday since Feb. 3, a few days prior to the SEC halt.Before the pandemic hit, the San Diego-based company had been focusing on Hemopurifier’s potential use in head and neck cancer, following years of testing it in infectious diseases without gaining U.S. approval to market the device.Even with today’s surge, Aethlon’s stock remains well off its 52-week high of $9 reached last July. Its market value was below $30 million mid-Thursday.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- 06/18/2020
|
Aethlon Announces FDA Approval of IDE Supplement for COVID-19 Patients
|
Aethlon Announces FDA Approval of IDE Supplement for COVID-19 Patients
- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the U.S. Food and Drug Administration (FDA) has approved a supplement to the Company's existing Investigational Device Exemption (IDE) for the Company's Hemopurifier® in viral disease to allow for the testing of the Hemopurifier in patients with SARS-CoV-2/COVID-19 in a new feasibility study.
- 06/18/2020
|
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.15%
- U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.15%
- 06/18/2020
|
Aethlon Medical To Release Fourth Quarter Financial Results and Host Conference Call on June 25, 2020
- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its fourth quarter fiscal year 2020, ended March 31, 2020, at 4:15pm Eastern time on Thursday, June 25, 2020.
- 06/16/2020
|
Medical Membranes Market Gross Margin, Competitive Landscape and Forecast By Key Players: 3M, NIPRO, GENERAL ELECTRIC, Merck KGaA, Koch Membrane Systems, Inc, Sartorius AG
- May 25, 2020 (CDN Newswire via Comtex) --
Global "Medical Membranes Market" analysis report is a historical overview and all-inclusive study on the current...
- 05/25/2020
|
Global Exosome Diagnostics and Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product, Service, Application & End-user - ResearchAndMarkets.com
|
Stop Chasing Coronavirus Plays Like Moderna Stock
- Stocks like MRNA stock have soared on hopes they will benefit from the coronavirus pandemic. But history shows few, if any, actually will.
- 03/25/2020
|
Aethlon Announces Issuance of European Patent for the Hemopurifier® in Cancer
- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in global health, announced today that it has received European Patent No. 1,993,600 ("the '600 Patent") entitled "Extracorporeal Removal of Microvesicular Particles." The '600 patent embodies Aethlon's Hemopurifier® technology designed for the depletion of immune suppressive, and potentially cancer-promoting, exosomes from the circulatory system.
- 03/24/2020
|
AEMD: Coronavirus 2019 (COVID-19) Could Represent New Opportunity for AEMD
- By Brian Marckx, CFA NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Fiscal Q3 2020 Financials, Operational Update Aethlon (NASDAQ:AEMD) reported fiscal Q3 2020 financial results and provided an operational update. Relative to the latter, which we discuss in more detail below, highlights include the possibility that the Hemopurifier might be tested as a potential therapy against the ongoing
- 03/06/2020
|
NVAX, INO among premarket gainers
- Digirad (NASDAQ:DRAD) +63% on Q4 results.Enzo Biochem (NYSE:ENZ) +50% on launch of coronavirus testing service.NanoViricides (NYSEMKT:NNVC) +34% on coronavirus drug progress.TEGNA (NYSE:TGNA) +28% on
- 03/06/2020
|
24 Stocks Moving in Friday's Pre-Market Session
- Gainers
NanoViricides, Inc. (NYSE: NNVC) shares rose 41.7% to $11.45 in pre-market trading after Small Caps Daily issued a press release discussing the company's coronavirus...
- 03/06/2020
|
18 Medical Stocks To Watch Amid The Coronavirus Outbreak
- Airlines, hotels, casinos and other stocks continue to fall as fear of the coronavirus grows worldwide and all but halts activity in the virus epicenter of Wuhan, China. Alpha Pro Tech, Ltd. (NYSE: APT) manufactures masks and protective apparel — goods already in high demand in China. Lakeland Industries
- 02/25/2020
|
Securities and Exchange Commission (SEC) Order for Halt in trading of Aethlon Medical Stock Expires
- On February 7, 2020, the Securities and Exchange Commission (SEC) issued an Order of Suspension of Trading (the "SEC Order"), temporarily suspending trading in Aethlon Medical, Inc. ("Aethlon" or the "Company")(NASDAQ:AEMD) stock for a period of ten trading days. The SEC Order stated that the suspension was due to concerns regarding the accuracy and adequacy of information in the marketplace that appeared to be disseminated by third party promoters and recent and unusual market activity since at least January 22, 2020. This trading halt has expired and the Company's shares resumed trading today on NASDAQ under the trading symbol AEMD.
- 02/24/2020
|
Edited Transcript of AEMD earnings conference call or presentation 10-Feb-20 9:30pm GMT
- Q3 2020 Aethlon Medical Inc Earnings Call
- 02/17/2020
|
Investors Who Bought Aethlon Medical (NASDAQ:AEMD) Shares Five Years Ago Are Now Down 98%
- Over the last month the Aethlon Medical, Inc. (NASDAQ:AEMD) has been much stronger than before, rebounding by 34%. But...
- 02/13/2020
|
Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update
- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its third quarter ended December 31, 2019 and provided an update on recent developments.
- 02/10/2020
|
Securities and Exchange Commission (SEC) Order for Halt in trading of Aethlon Medical (NASDAQ:AEMD) Stock
- (NASDAQ:AEMD) -- On February 7, 2020, the Securities and Exchange Commission (SEC) issued an Order of Suspension of Trading (the "SEC Order"), temporarily suspending trading in Aethlon Medical, Inc. ("Aethlon" or the "Company") stock for a period of ten days. The SEC Order stated that the suspension was due to concerns regarding the accuracy and adequacy of information in the marketplace that appeared to be disseminated by third party promotors and recent and unusual market activity since at least January 22, 2020.
- 02/10/2020
|
The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight
- Biotech stocks recovered last week along with the broader markets, which bounced back from a China coronavirus-induced sell-off. Big pharma earnings took the spotlight, with Merck & Co., Inc. (NYSE: MRK ...
- 02/09/2020
|
Aethlon Medical To Release Third Quarter Financial Results and Host Conference Call on February 10, 2020
- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its third quarter fiscal year 2020, ended December 31, 2019, at 4:15pm Eastern time on Monday, February 10, 2020.
- 02/06/2020
|
AMZN, NAV among premarket gainers
- Navistar International (NYSE:NAV) +55% with Volkswagen finally making move for acquisition.NanoViricides (NYSEMKT:NNVC) +42% after confirming work on coronavirus treatment.Lianluo Smart (NASDAQ:LLIT)
- 01/31/2020
|
The Wuhan Coronavirus: 21 Stocks to Watch
- News like the Coronavirus can affect the stock market — either as a whole or just certain stocks and sectors. See how you can prepare.
- 01/29/2020
|
Healthcare tops premarket losers as Coronavirus worries deepen
- NanoViricides (NYSEMKT:NNVC) -23% after coronavirus breakout.Allied Healthcare Products (NASDAQ:AHPI) -19% after coronavirus breakout.Aethlon Medical (NASDAQ:AEMD) -16% after coronavirus breakout.Clev
- 01/28/2020
|
Tech Majors, Boeing, UPS And Tesla On Tap
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 01/25/2020
|
13 Coronavirus-Related Stocks To Watch Amid Wuhan Outbreak
- Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter. Alpha Pro Tech, Ltd. (NYSE: APT) manufactures masks and protective apparel — goods already in high demand in China. Lakeland Industries, Inc. (NASDAQ: LAKE) also produces protective clothes for high-risk workers, such as the medical professionals and public health officials exposing themselves to patients.
- 01/23/2020
|
The Zacks Analyst Blog Highlights: Novavax, NanoViricides, Aethlon Medical and Oncolytics Biotech
- The Zacks Analyst Blog Highlights: Novavax, NanoViricides, Aethlon Medical and Oncolytics Biotech
- 01/23/2020
|
Health stocks reverse coronavirus gains as one analyst says the market is overreacting
- Virus originating in Wuhan, China affected stock markets Tuesday, but one analyst said reactions were too strong.
- 01/22/2020
|
Aethlon Medical Announces Completion of $3.77 Million Registered Direct Offering
- Aethlon Medical, Inc. (Nasdaq:AEMD) ("Aethlon" or the "Company"), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the completion of its previously announced registered direct offering of 1,885,378 shares of its common stock, at a purchase price per share of $2.00, priced at-the-market under Nasdaq rules. Additionally, Aethlon issued to the purchasers unregistered warrants to purchase up to 942,689 shares of common stock. The warrants have an exercise price of $2.75 per share of common stock, are exercisable immediately and will expire five and one-half years from the issuance date.
- 01/22/2020
|
HEXO, NIO among premarket gainers
- One Stop Systems (NASDAQ:OSS) +56% reports prelim results.Genprex (NASDAQ:GNPX) +52%.Akcea Therapeutics (NASDAQ:AKCA) +14% as antisense candidate successful in mid-stage hypertriglyceridemia study.Tri
- 01/22/2020
|
Coronavirus Infects Wall Street: Stocks to Gain & Lose
- While travel-related stocks were hit hard on concerns over coronavirus, experimental vaccine companies rallied.
- 01/22/2020
|
Aethlon Medical Announces $3.77 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Aethlon Medical, Inc. (Nasdaq:AEMD) (the "Company"), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that it has entered into definitive agreements with certain institutional investors for the purchase in a registered direct offering of 1,885,378 shares of its common stock, at a purchase price per share of $2.00, priced at-the-market under Nasdaq rules. Additionally, Aethlon has agreed to issue to the investors unregistered warrants to purchase up to 942,689 shares of common stock. The warrants have an exercise price of $2.75 per share of common stock, will be exercisable immediately and will expire five and one-half years from the issuance date.
- 01/17/2020
|
New Medical Device That is Proving Effective Against the Worlds Toughest Viruses, Including: Ebola, Hep C, HIV, West Nile and Smallpox Wins FDA Designation "Breakthrough Device"
- /PRNewswire/ -- USA News Group – A new study published in the journal Molecular Therapy reports that researchers found a drug used in the treatment of HIV that...
- 01/15/2020
|
Aethlon Medical Announces Closing of $5 Million Public Offering
- Aethlon Medical, Inc. (Nasdaq: AEMD) (the "Company"), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the closing of the previously announced underwritten public offering of 3,333,334 shares of common stock (which includes pre-funded warrants to purchase shares of common stock in lieu thereof), and common warrants to purchase up to an aggregate of 3,333,334 shares of common stock at a public offering price of $1.50 per share. Each share of common stock (or pre-funded warrant in lieu thereof) was sold together with a common warrant to purchase one share of common stock. The common warrants have an exercise price of $1.50 per share, are immediately exercisable, and will expire five years from the date of issuance. The Company has also granted the underwriter a 45-day option to purchase up to an additional 499,999 shares of common stock and/or common warrants to purchase up to 499,999 shares of common stock, at the public offering price, less underwriting discounts and commission.
- 12/17/2019
|
Aethlon Medical Announces Pricing of $5 Million Public Offering
- Aethlon Medical, Inc. (Nasdaq:AEMD) (the "Company"), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the pricing of an underwritten public offering of 3,333,334 shares of common stock (which includes pre-funded warrants to purchase shares of common stock in lieu thereof), and common warrants to purchase up to an aggregate of 3,333,334 shares of common stock at a public offering price of $1.50 per share. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with a common warrant to purchase one share of common stock. The common warrants have an exercise price of $1.50 per share, are immediately exercisable, and will expire five years from the date of issuance. The Company has granted the underwriter a 45-day option to purchase up to an additional 499,999 shares of common stock and/or common warrants to purchase up to 499,999 shares of common stock, at the public offering price, less underwriting discounts and commission.
- 12/13/2019
|
Here's Why We Worry About Aethlon Medical's (NASDAQ:AEMD) Cash Burn Situation
- There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- 11/15/2019
|
Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update
- SAN DIEGO , Nov. 1, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, ...
- 11/01/2019
|
Aethlon Medical To Release Second Quarter Financial Results and Host Conference Call on November 1, 2019
- SAN DIEGO, Oct. 29, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its second quarter fiscal year 2020, ended September 30, 2019, at 4:15pm Eastern time on Friday, November 1, 2019. Management will host a conference call on Friday, November 1, 2019 at 4:30pm Eastern time to review financial results and recent corporate developments. To listen to the call by phone, interested parties within the U.S. should call 1-844-836-8741 and International callers should call 1-412-317-5442.
- 10/29/2019
|
AEMD: IDE Approved. Hemopurifier U.S. Clinical Cancer Program On-Deck…
- By Brian Marckx, CFA NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT When Aethlon Medical (NASDAQ:AEMD) reported fiscal Q1 2020 financial results in August, management noted that they anticipated imminent filing of an Investigational Device Exemption (IDE) seeking approval to initiate U.S.-based clinical studies for their Hemopurifier device in cancer patients. Not only did that filing
- 10/28/2019
|
Xconomy: Exosomes Head to Wall Street As Codiak Biosciences Lines Up IPO
- Do Wall Street investors believe that exosomes, the tiny bubbles once thought to be just cellular garbage bins, may be the key to treating a slew of
- 04/30/2019
|
Xconomy: VCs Put More Dollars Into Exosomes as Codiak Bio Lands $76M
- Codiak BioSciences, the startup run by former Biogen (NASDAQ: ]) research chief Doug Williams, has rung up its third big round of cash in two years. The
- 11/29/2017
|
